Skip to content
HowShorted

Relay Therapeutics, Inc. short interest in 2023

In 2023, Relay Therapeutics, Inc.'s disclosed short interest ran from 15.43% of shares outstanding on 13 Jan 2023 to 9.74% on 29 Dec 2023, a change of -5.69 percentage points. The year's high was 17.66% on 15 May 2023 and its low 9.74% on 29 Dec 2023, averaging 14.86% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 28.38 days on 31 Aug 2023. Full history: Relay Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Relay Therapeutics, Inc. in 2023

2023 in figures

Start of year
15.43% (13 Jan 2023)
End of year
9.74% (29 Dec 2023)
Change
-5.69 pp
High
17.66% (15 May 2023)
Low
9.74% (29 Dec 2023)
Average
14.86%
Highest days to cover
28.38 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

Relay Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202315.43%8.37
31 Jan 202314.38%13.47
15 Feb 202314.28%16.78
28 Feb 202314.71%18.1510-K filed, results (8-K)
15 Mar 202314.83%16.81
31 Mar 202315.64%18.12
14 Apr 202316.16%12.65
28 Apr 202316.28%5.99
15 May 202317.66%14.4010-Q filed, results (8-K)
31 May 202317.40%15.45
15 Jun 202317.34%17.88
30 Jun 202316.84%12.50
14 Jul 202316.32%20.98
31 Jul 202316.14%22.49
15 Aug 202316.95%22.7810-Q filed, results (8-K)
31 Aug 202316.28%28.38
15 Sep 202316.44%14.92
29 Sep 202315.88%20.01
13 Oct 202311.28%10.27
31 Oct 202311.70%11.46
15 Nov 202311.88%11.6210-Q filed, results (8-K)
30 Nov 202311.87%16.49
15 Dec 202311.11%10.04
29 Dec 20239.74%13.83

See also: Relay Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.